Abstract:Photodynamic therapy (PDT) is a promising strategy for cancer treatment. It can not only generate reactive oxygen species (ROS) to cause the chemical damage of tumor cells in the presence of enough oxygen but also promote the antitumor immunity of T cells through enhancing the production of interferon γ (IFN-γ). However, one phenomenon is ignored so far that the enhanced production of IFN-γ caused by PDT may significantly increase the expression of programmed death-ligand 1 (PD-L1) on the tumor cell membrane and thus could inhibit the immune killing effects of T cells. Herein, we report the construction of a composite by loading metformin (Met) and IR775 into a clinically usable liposome as a two-in-one nanoplatform (@Lip) to solve this problem. The @Lip could reverse tumor hypoxia to enhance ROS production to elicit more chemical damage. Besides, the overexpression of PD-L1 by PDT was also effectively down-regulated. These therapeutic benefits including decreased PD-L1 expression, alleviated T cell exhaustion, and reversed tumor hypoxia successfully suppressed both the primary and abscopal tumor growth in bladder and colon cancers, respectively. Combining with its excellent biocompatibility, our results indicate that this @Lip system has great potential to become a highly effective cancer therapy modality.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c21743?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c21743</a>.UV–vis spectra of Met, , IR775, and ; dilution and storage stability analysis of @Lip; chromatogram of Met; standard curve of Met and IR775; cellular uptake of @Lip; representative immunofluorescence images of pimonidazole; flow cytometry results of ROS in MB49 cells; cell viability of CT26 cells after different treatments; immunofluorescence images of PD-L1 in MB49 and CT26 cells; Western blot analysis of the expression of PD-L1 in MB49 and CT26 cells; flow cytometry analysis of the expression of PD-L1 in MB49 and CT26 cells; analysis of the expression of PD-L1 in the CT26 tumor model by Western blotting; immunofluorescence images of CD3+, CD4+, and CD8+ T cells in CT26 tumors; expression of IFN-γ in the MB49 and CT26 tumor tissues; photograph of collected MB49 and CT26 tumors after different treatments; relative body weight of MB49 and CT26 tumor-bearing mice after different treatments; representative images of Ki67, TUNEL, and H&E staining in the MB49 and CT26 tumors after different treatments; expression of IFN-γ in the MB49 tumor tissues after antitumor treatment; biosafety evaluation of @Lip; The primary tumor growth curves for MB49 tumor-bearing mice after different treatments; distal tumor growth curves of each mouse in different treatment groups (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c21743/suppl_file/am0c21743_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Pegylated liposomal mitoxantrone modulates tumor immune landscape to boost PD-L1 blockade therapy

Bimetallic Peroxide-Based Nanotherapeutics for Immunometabolic Intervention and Induction of Immunogenic Cell Death to Augment Cancer Immunotherapy

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer

Near‐Infrared Responsive Membrane Nanovesicles Amplify Homologous Targeting Delivery of Anti‐PD Immunotherapy Against Metastatic Tumors

Platelet Membrane Camouflaged AIEgen‐mediated Photodynamic Therapy Improves the Effectiveness of Anti‐pd‐l1 Immunotherapy in Large‐burden Tumors

Amplified antitumor efficacy by a targeted drug retention and chemosensitization strategy-based “combo” nanoagent together with PD-L1 blockade in reversing multidrug resistance

Nanomedicine Integrating the Lipidic Derivative of 5-Fluorouracil, Miriplatin and PD-L1 Sirna for Enhancing Tumor Therapy

Microfluidic PLGA microcapsules with PD-L1 aptamers and docetaxel encapsulation for enhancing tumor immunity

Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy

Reversing the negative effect of adenosine A1 receptor-targeted immunometabolism modulation on melanoma by a co-delivery nanomedicine for self-activation of anti-PD-L1 DNAzyme

Harnessing PD-1 cell membrane-coated paclitaxel dimer nanoparticles for potentiated chemoimmunotherapy

Tumor cell–derived microparticles induced by methotrexate augment T-cell antitumor responses by down-regulating expression of PD-1 in neutrophils

Design of Mitoxantrone‐Loaded Biomimetic Nanocarrier with Sequential Photothermal/Photodynamic/Chemotherapy Effect for Synergized Immunotherapy

Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors

LHD-Modified Mechanism-Based Liposome Coencapsulation of Mitoxantrone and Prednisolone Using Novel Lipid Bilayer Fusion for Tissue-Specific Colocalization and Synergistic Antitumor Effects.

Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade

Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy

Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy

Combination treatment with immunogenic and anti-PD-L1 polymer-drug conjugates of advanced tumors in a transgenic MMTV-PyMT mouse model of breast cancer

GSH-responsive camptothecin prodrug-based hybrid micellar nanoparticles enable antitumor chemo-immunotherapy by PD-L1 knockdown